Cat. No.: HY-109115

Fosifloxuridine nafalbenamide

Name: Fosifloxuridine nafalbenamide
Brand: MedChemExpress
SKU: HY-109115
Price: 200.00 USD
Availability: InStock
Rating: 5 (2 reviews)

(Synonyms: NUC-3373)

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Fosifloxuridine nafalbenamide (NUC-3373), a pyrimidine nucleotide analogue, is a Thymidylate synthase inhibitor. Fosifloxuridine nafalbenamide has anticancer activity. Fosifloxuridine nafalbenamide has the potential to evoke a host immune response and enhance immunoresearch.

For research use only. We do not sell to patients.

Purity: 96.31%
CAS No.: 1332837-31-6
Formula: C₂₉H₂₉FN₃O₉P
Molecular Weight:613.53

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Fosifloxuridine nafalbenamide Chemical Structure

CAS No.: 1332837-31-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	IC₅₀	0.05 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting	[PMID: 21892829]
CCRF-CEM	IC₅₀	0.068 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against human CEM/0 cells after 72 hrs by cell counting Cytostatic activity against human CEM/0 cells after 72 hrs by cell counting	[PMID: 21892829]
CCRF-CEM	IC₅₀	0.13 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of dipyridamole Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of dipyridamole	[PMID: 21892829]
CCRF-CEM	IC₅₀	0.26 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of NBMPR Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of NBMPR	[PMID: 21892829]
CCRF-CEM	IC₅₀	0.31 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against thymidine-kinase deficient human CEM cells after 72 hrs by cell counting Cytostatic activity against thymidine-kinase deficient human CEM cells after 72 hrs by cell counting	[PMID: 21892829]
CCRF-CEM	IC₅₀	0.6 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against ENT1 transporter-deficient human CEM cells after 72 hrs by cell counting Cytostatic activity against ENT1 transporter-deficient human CEM cells after 72 hrs by cell counting	[PMID: 21892829]
COLO 205	IC₅₀	0.14 μM Compound: NUC373	Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
HeLa	IC₅₀	0.065 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against human HeLa cells after 72 hrs by cell counting Cytostatic activity against human HeLa cells after 72 hrs by cell counting	[PMID: 21892829]
HeLa	IC₅₀	2.5 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against thymidine-kinase deficient human HeLa cells after 72 hrs by cell counting Cytostatic activity against thymidine-kinase deficient human HeLa cells after 72 hrs by cell counting	[PMID: 21892829]
HepG2	IC₅₀	24.5 μM Compound: NUC373	Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
HT-29	IC₅₀	0.52 μM Compound: NUC373	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
L1210	IC₅₀	0.025 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against Mycoplasma hyorhinis-infected mouse L1210 cells after 48 hrs by cell counting Cytostatic activity against Mycoplasma hyorhinis-infected mouse L1210 cells after 48 hrs by cell counting	[PMID: 21892829]
L1210	IC₅₀	0.045 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against thymidine-kinase deficient mouse L1210 cells after 48 hrs by cell counting Cytostatic activity against thymidine-kinase deficient mouse L1210 cells after 48 hrs by cell counting	[PMID: 21892829]
MIA PaCa-2	IC₅₀	1.47 μM Compound: NUC373	Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
NCI-H1975	IC₅₀	72 μM Compound: NUC373	Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
OVCAR-3	IC₅₀	6.91 μM Compound: NUC373	Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
RPMI-8226	IC₅₀	5.9 μM Compound: NUC373	Cytotoxicity against human RPMI-8226 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human RPMI-8226 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
SK-MES-1	IC₅₀	0.32 μM Compound: NUC373	Cytotoxicity against human SK-MES-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human SK-MES-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]

In Vitro

Fosifloxuridine nafalbenamide induces the release of damage-associated molecular patterns (DAMPs), with increased expression of calreticulin (CRT) at the cell surface and concomitant loss of nuclear nuclear high mobility group box protein 1 (HMGB1)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Fosifloxuridine nafalbenamide exhibits anti-cancer activity in HT-29 nude mouse xenograft models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1332837-31-6
Appearance Solid
Molecular Weight 613.53
Formula C₂₉H₂₉FN₃O₉P
Color White to off-white
SMILES

O=P(OC[C@H]1O[C@@H](N(C=C(F)C2=O)C(N2)=O)C[C@@H]1O)(N[C@@H](C)C(OCC3=CC=CC=C3)=O)OC4=CC=CC5=C4C=CC=C5
Synonyms

NUC-3373
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

Sci Data

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]

2024 Sep 19;11(1):1024. PMID: 39300112
J Pharmacol Exp Ther

A 5'-(R)-CH3-substituted 5-fluoro-2'-deoxyuridine monophosphate reduces off-target toxicities while maintaining efficacy in a colorectal cancer model. [Abstract]

2025 Nov 10;393(1):103773. PMID: 41352320

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (162.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6299 mL

8.1496 mL

16.2991 mL

5 mM

0.3260 mL

1.6299 mL

3.2598 mL

10 mM

0.1630 mL

0.8150 mL

1.6299 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Fiona G. McKissock, et al. Abstract 1848: NUC-3373 induces ER stress and the release of damage associated molecular patterns in colorectal cancer cells. Cancer Res August 15 2020 (80) (16 Supplement) 1848.

[2]. Essam A. Ghazaly, et al. Abstract B46: NUC-3373: A novel pyrimidine nucleotide analogue that overcomes key cancer drug resistance limiting patient survival. Mol Cancer Ther December 1 2015 (14) (12 Supplement 2) B46.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6299 mL	8.1496 mL	16.2991 mL	40.7478 mL
	5 mM	0.3260 mL	1.6299 mL	3.2598 mL	8.1496 mL
	10 mM	0.1630 mL	0.8150 mL	1.6299 mL	4.0748 mL
	15 mM	0.1087 mL	0.5433 mL	1.0866 mL	2.7165 mL
	20 mM	0.0815 mL	0.4075 mL	0.8150 mL	2.0374 mL
	25 mM	0.0652 mL	0.3260 mL	0.6520 mL	1.6299 mL
	30 mM	0.0543 mL	0.2717 mL	0.5433 mL	1.3583 mL
	40 mM	0.0407 mL	0.2037 mL	0.4075 mL	1.0187 mL
	50 mM	0.0326 mL	0.1630 mL	0.3260 mL	0.8150 mL
	60 mM	0.0272 mL	0.1358 mL	0.2717 mL	0.6791 mL
	80 mM	0.0204 mL	0.1019 mL	0.2037 mL	0.5093 mL
	100 mM	0.0163 mL	0.0815 mL	0.1630 mL	0.4075 mL

Bioz

Keywords

Fosifloxuridine nafalbenamide

2 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Fosifloxuridine nafalbenamide

10-Formyl-5,8-dideazafolic acid

Nolatrexed dihydrochloride